Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2000

View Archived Issues

Avant Immunotherapeutics to acquire Megan Health

Favorable pharmacokinetic and tolerability profile for Angiozyme in humans

Repligen reports update on product development programs

VX-175 enters series of phase III trials

Dusa moves Levulan into phase I/II for the treatment of acne

TP-10 undergoes phase II evaluation in adult cardiac surgery patients

NicOx's HCT-1026 shows promise for treatment of skin inflammation

Virax's HIV vaccine VIR-201 approved for human study

Company Profile: EpiCept

Acadia succeeds in designing selective 5-HT2A inverse agonists/antagonists based on spiperone

Yamanouchi discovers novel class of potent, nonsteroidal human 5alpha-reductase inhibitors

Phytomedicine continues to show promise for GI inflammatory conditions

Synthetic immunomodulatory peptide inhibits production of proinflammatory cytokines in CD

PK-11195 is able to sensitize cholangiocarcinoma cells to radiation-induced apoptosis

Immediate withdrawal of Lotronex in U.S. announced by Glaxo Wellcome

Amarin licenses U.S. rights to LAX-101 for Huntington's disease

8th UEGW news: alendronate is safe and effective for increasing BMD in Crohn's disease

Fampridine-SR enters phase II trials for MS

Successful completion of Alkermes' first clinical trial with inhaled insulin

Enhanced expression of p21 associated with responses to rAd-p53 gene therapy in NSCLC

Anticoagulants targeting thrombin developed at ADIR

Novel series of cognition enhancers claimed in recent patent by ADIR

Fujisawa synthesizes cyclic hexapeptides with broad-spectrum antifungal activity

Piperidine-based renin inhibitors and their use described by Roche

Integrin alpha4beta1 inhibitors disclosed by AstraZeneca scientists

Tri- and di-aryl acid PPAR modulators claimed by Aventis for diabetes and related disorders

Lyotropic Therapeutics and Elan establish alliance for development of unique drug delivery system

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...